Allogene Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

CEO

David D. Chang

CEODavid D. Chang

Employees

229

Employees229

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

2017

Founded2017

Employees

229

Employees229

ALLO Key Statistics

Market cap

265.15M

Market cap265.15M

Price-Earnings ratio

-1.01

Price-Earnings ratio-1.01

Dividend yield

—

Dividend yield—

Average volume

4.13M

Average volume4.13M

High today

$1.23

High today$1.23

Low today

$1.12

Low today$1.12

Open price

$1.12

Open price$1.12

Volume

6.05M

Volume6.05M

52 Week high

$3.78

52 Week high$3.78

52 Week low

$0.8621

52 Week low$0.8621

Analyst ratings

79%

of 14 ratings

Buy

78.6%

Hold

21.4%

Sell

People also own

Based on the portfolios of people who own ALLO. This list is generated using Robinhood data, and it’s not a recommendation.